BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 35923120)

  • 21. Radical prostatectomy in men aged >or=70 years: effect of age on upgrading, upstaging, and the accuracy of a preoperative nomogram.
    Richstone L; Bianco FJ; Shah HH; Kattan MW; Eastham JA; Scardino PT; Scherr DS
    BJU Int; 2008 Mar; 101(5):541-6. PubMed ID: 18257855
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cribriform morphology predicts upstaging after radical prostatectomy in patients with Gleason score 3 + 4 = 7 prostate cancer at transrectal ultrasound (TRUS)-guided needle biopsy.
    Keefe DT; Schieda N; El Hallani S; Breau RH; Morash C; Robertson SJ; Mai KT; Belanger EC; Flood TA
    Virchows Arch; 2015 Oct; 467(4):437-42. PubMed ID: 26229020
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ability of prostate-specific antigen (PSA) density to predict an upgrade in Gleason score between initial prostate biopsy and prostatectomy diminishes with increasing tumour grade due to reduced PSA secretion per unit tumour volume.
    Corcoran NM; Casey RG; Hong MK; Pedersen J; Connolly S; Peters J; Harewood L; Gleave ME; Costello AJ; Hovens CM; Goldenberg SL
    BJU Int; 2012 Jul; 110(1):36-42. PubMed ID: 22085203
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Increased body mass index as a risk factor in localized prostate cancer treated by radical prostatectomy.
    Goris Gbenou MC; Peltier A; Schulman CC; Velthoven Rv
    Urol Oncol; 2016 Jun; 34(6):254.e1-6. PubMed ID: 26822075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cross-correlation of serum chromogranin A, %-F-PSA and bone scans in prostate cancer diagnosis.
    Ahel MZ; Kovacic K; Tarle M
    Anticancer Res; 2001; 21(2B):1363-6. PubMed ID: 11396214
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Preoperative prostate-specific antigen isoform p2PSA and its derivatives, %p2PSA and prostate health index, predict pathologic outcomes in patients undergoing radical prostatectomy for prostate cancer.
    Guazzoni G; Lazzeri M; Nava L; Lughezzani G; Larcher A; Scattoni V; Gadda GM; Bini V; Cestari A; Buffi NM; Freschi M; Rigatti P; Montorsi F
    Eur Urol; 2012 Mar; 61(3):455-66. PubMed ID: 22078333
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chromogranin a concentration as a serum marker to predict prognosis after endocrine therapy for prostate cancer.
    Isshiki S; Akakura K; Komiya A; Suzuki H; Kamiya N; Ito H
    J Urol; 2002 Feb; 167(2 Pt 1):512-5. PubMed ID: 11792908
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Postoperative upgrading of prostate cancer in men ≥75 years: a propensity score-matched analysis.
    Herlemann A; Buchner A; Kretschmer A; Apfelbeck M; Stief CG; Gratzke C; Tritschler S
    World J Urol; 2017 Oct; 35(10):1517-1524. PubMed ID: 28493044
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The Impact of Prostate Cancer Upgrading and Upstaging on Biochemical Recurrence and Cancer-Specific Survival.
    Bakavičius A; Drevinskaitė M; Daniūnaitė K; Barisienė M; Jarmalaitė S; Jankevičius F
    Medicina (Kaunas); 2020 Feb; 56(2):. PubMed ID: 32033148
    [No Abstract]   [Full Text] [Related]  

  • 30. Low serum total testosterone level as a predictor of upstaging and upgrading in low-risk prostate cancer patients meeting the inclusion criteria for active surveillance.
    Ferro M; Lucarelli G; Bruzzese D; Di Lorenzo G; Perdonà S; Autorino R; Cantiello F; La Rocca R; Busetto GM; Cimmino A; Buonerba C; Battaglia M; Damiano R; De Cobelli O; Mirone V; Terracciano D
    Oncotarget; 2017 Mar; 8(11):18424-18434. PubMed ID: 27793023
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The relationship between preoperative prostate-specific antigen and biopsy Gleason sum in men undergoing radical retropubic prostatectomy: a novel assessment of traditional predictors of outcome.
    Pierorazio P; Desai M; McCann T; Benson M; McKiernan J
    BJU Int; 2009 Jan; 103(1):38-42. PubMed ID: 18778352
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Preoperative PSA level significantly associated with interval to biochemical progression after radical retropubic prostatectomy.
    Gonzalez CM; Roehl KA; Antenor JV; Blunt LW; Han M; Catalona WJ
    Urology; 2004 Oct; 64(4):723-8. PubMed ID: 15491709
    [TBL] [Abstract][Full Text] [Related]  

  • 33. After radical retropubic prostatectomy 'insignificant' prostate cancer has a risk of progression similar to low-risk 'significant' cancer.
    Sengupta S; Blute ML; Bagniewski SM; Inman B; Leibovich BC; Slezak JM; Myers RP; Zincke H
    BJU Int; 2008 Jan; 101(2):170-4. PubMed ID: 18173824
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
    Sciarra A; Gentile V; Monti S; Dattilo C; Autran Gomez A; Salciccia S; Pannunzi LP; Toscano V; Di Silverio F
    Urol Int; 2008; 80(1):68-73. PubMed ID: 18204237
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Serum chromogranin-A in advanced prostate cancer.
    Ferrero-Poüs M; Hersant AM; Pecking A; Brésard-Leroy M; Pichon MF
    BJU Int; 2001 Nov; 88(7):790-6. PubMed ID: 11890255
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The possible role of chromogranin A as a prognostic factor in organ-confined prostate cancer.
    Grimaldi F; Valotto C; Barbina G; Visentini D; Trianni A; Cerruto MA; Zattoni F
    Int J Biol Markers; 2006; 21(4):229-34. PubMed ID: 17177161
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Soluble E-cadherin and IL-6 serum levels in patients affected by prostate cancer before and after prostatectomy.
    Iacopino F; Pinto F; Bertaccini A; Calarco A; Proietti G; Totaro A; Martorana G; Bassi P; Sica G
    Oncol Rep; 2012 Jul; 28(1):370-4. PubMed ID: 22552350
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Utility of Gleason pattern 4 morphologies detected on transrectal ultrasound (TRUS)-guided biopsies for prediction of upgrading or upstaging in Gleason score 3 + 4 = 7 prostate cancer.
    Flood TA; Schieda N; Keefe DT; Breau RH; Morash C; Hogan K; Belanger EC; Mai KT; Robertson SJ
    Virchows Arch; 2016 Sep; 469(3):313-9. PubMed ID: 27394432
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Experience with neoadjuvant diethylstilboestrol and radical prostatectomy in patients with locally advanced prostate cancer.
    Aprikian AG; Fair WR; Reuter VE; Sogani P; Herr H; Russo P; Sheinfeld J
    Br J Urol; 1994 Nov; 74(5):630-6. PubMed ID: 7530128
    [TBL] [Abstract][Full Text] [Related]  

  • 40. No detrimental effect of a positive family history on postoperative upgrading and upstaging in men with low risk and favourable intermediate-risk prostate cancer: implications for active surveillance.
    Herkommer K; Maier N; Ankerst DP; Schiele S; Gschwend JE; Meissner VH
    World J Urol; 2021 Jul; 39(7):2499-2506. PubMed ID: 33048258
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.